Ad

HLS – HLS Therapeutics Inc

Compliant

★★☆☆☆

HLS Therapeutics Inc is Shariah compliant. The company’s financials pass two standards and fail in three.

$316,850,691

Market cap

93.5%

Revenue Growth

BUY

Analysts' Rating

Ad

Recommendation Rating

1.67

1

2

3

4

5

1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Analysts’ Price Targets

Mean 22.18

Low: 19.37

High: 27.9

Total Analysts: 7

Company Profile

HLS Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company is focused on developing clinically differentiated pharmaceutical products in the specialty central nervous system (CNS) and cardiovascular (CV) markets. Its products include Vascepa, Trinomia, Clozaril, CSAN Pronto, PERSERIS and MyCare Psychiatry/MyCare Insite. Its lead product, Clozaril, is an atypical antipsychotic indicated in the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Vascepa capsules reduce the risk of cardiovascular events, such as cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization, or hospitalization for unstable angina in statin-treated patients with elevated triglycerides.

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan

Ad

Responses